Free Trial
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
$1.70
+11.8%		$3.32
$1.46
▼
$32.55
$1.56M-0.753,939 shs183,809 shs
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
$0.33
-0.6%		$0.46
$0.32
▼
$2.39
$1.18M0.9138,766 shs54,579 shs
Venus Concept Inc. stock logo
VERO
Venus Concept
$0.31
$0.31
$0.25
▼
$12.93
$442K-0.062.28 million shsN/A
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
$0.10
+2.2%		$0.15
$0.09
▼
$2.72
$1.55M6.378.17 million shs738,251 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover
The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
0.00%-16.02%-51.13%-83.64%-90.90%
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
0.00%-12.36%-28.62%-62.10%-80.95%
Venus Concept Inc. stock logo
VERO
Venus Concept
0.00%0.00%0.00%0.00%-83.91%
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
0.00%-17.66%-37.07%-70.51%-96.35%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
$1.70
+11.8%		$3.32
$1.46
▼
$32.55
$1.56M-0.753,939 shs183,809 shs
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
$0.33
-0.6%		$0.46
$0.32
▼
$2.39
$1.18M0.9138,766 shs54,579 shs
Venus Concept Inc. stock logo
VERO
Venus Concept
$0.31
$0.31
$0.25
▼
$12.93
$442K-0.062.28 million shsN/A
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
$0.10
+2.2%		$0.15
$0.09
▼
$2.72
$1.55M6.378.17 million shs738,251 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover
The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
0.00%-16.02%-51.13%-83.64%-90.90%
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
0.00%-12.36%-28.62%-62.10%-80.95%
Venus Concept Inc. stock logo
VERO
Venus Concept
0.00%0.00%0.00%0.00%-83.91%
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
0.00%-17.66%-37.07%-70.51%-96.35%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
2.00
Hold$42.002,370.59% Upside
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
1.00
SellN/AN/A
Venus Concept Inc. stock logo
VERO
Venus Concept
1.00
SellN/AN/A
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
2.25
Hold$2.802,822.76% Upside

Current Analyst Ratings Breakdown

Latest VERO, AMIX, VVOS, and BBLG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/26/2026
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
10/22/2026
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
10/15/2026
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
(Data available from 11/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
N/AN/AN/AN/A$10.85 per shareN/A
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
N/AN/AN/AN/A$3.00 per shareN/A
Venus Concept Inc. stock logo
VERO
Venus Concept
$58.88M0.01N/AN/A$4.30 per share0.07
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
$20.90M0.06N/AN/A($0.16) per share-0.60
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
-$16.72M-$41.57N/AN/AN/AN/A-267.73%-216.75%11/11/2026 (Estimated)
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
-$3.11M-$1.17N/AN/AN/AN/A-57.07%-52.54%11/13/2026 (Estimated)
Venus Concept Inc. stock logo
VERO
Venus Concept
-$47M-$48.84N/AN/AN/A-92.76%-1,904.25%-85.22%N/A
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
-$21.17M-$1.90N/AN/AN/A-122.00%-2,325.64%-102.01%11/18/2026 (Estimated)

Latest VERO, AMIX, VVOS, and BBLG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/18/2026Q3 2026
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
-$0.30N/AN/AN/A$5.48 millionN/A
11/13/2026N/A
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
-$0.19N/AN/AN/AN/AN/A
11/11/2026Q2 2027
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
-$2.62N/AN/AN/AN/AN/A
10/26/2026Q3 2026
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
-$0.19-$0.17+$0.02-$0.17N/AN/A
8/14/2026Q2 2026
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
-$0.39-$0.43-$0.04-$0.43N/AN/A
8/14/2026Q2 2026
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
-$0.41-$0.31+$0.10-$0.31$5.63 million$5.15 million
8/12/2026Q1 2027
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
-$6.40-$5.02+$1.38-$5.02N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
N/AN/AN/AN/AN/A
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
N/AN/AN/AN/AN/A
Venus Concept Inc. stock logo
VERO
Venus Concept
N/AN/AN/AN/AN/A
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
N/A
4.85
4.85
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
N/A
13.37
13.37
Venus Concept Inc. stock logo
VERO
Venus Concept
1.59
0.90
0.59
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
N/A
0.21
0.21

Institutional Ownership

CompanyInstitutional Ownership
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
10.78%
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
34.30%
Venus Concept Inc. stock logo
VERO
Venus Concept
87.41%
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
26.35%

Insider Ownership

CompanyInsider Ownership
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
5.50%
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
5.00%
Venus Concept Inc. stock logo
VERO
Venus Concept
28.04%
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
2.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
11971,000918,000N/A
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
23.39 million3.22 millionNot Optionable
Venus Concept Inc. stock logo
VERO
Venus Concept
4101.42 million1.03 millionNot Optionable
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
26813.90 million19.84 millionOptionable

Recent News About These Companies

Head to Head Contrast: Intelligent Bio Solutions (NASDAQ:INBS) versus Vivos Therapeutics (NASDAQ:VVOS)
November 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31173411
CORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
October 29, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/ACCESS%20Newswire/8531730/correction-sod-sciences-welcomes-vivos-therapeutics-as-strategic-investor-and-partner-in-the-rebalu-primed-cell-test/
Vivos Therapeutics Director Anja Krammer Granted 12,000 Stock Options in September 2026
October 29, 2026  |  kalkinemedia.comK
Vivos Therapeutics Director Mark F. Lindsay Granted 12,000 Stock Options at $0.18 Exercise Price
October 28, 2026  |  kalkinemedia.comK
Vivos Therapeutics Director Ralph Elias Green Granted 12,000 Stock Options at $0.18 Exercise Price
October 27, 2026  |  kalkinemedia.comK
Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard
October 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vivos-therapeutics-reports-nasdaq-confirmation-of-compliance-with-continued-listing-shareholders-equity-standard-1036648709
Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders' Equity Standard
October 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/21/3385390/0/en/vivos-therapeutics-reports-nasdaq-confirmation-of-compliance-with-continued-listing-shareholders-equity-standard.html
SOD SCIENCES INC.: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
October 20, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-10/69886525-sod-sciences-inc-sod-sciences-welcomes-vivos-therapeutics-as-strategic-investor-and-partner-in-the-rebalu-primed-cell-test-200.htm
SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
October 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/sod-sciences-welcomes-vivos-therapeutics-154000043.html
Vivos Therapeutics Buys 11% of SOD Sciences, Gains 50% Stake in Diagnostic Test
October 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vivos-therapeutics-buys-11-sod-215429933.html
Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through ...
October 19, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vivos-therapeutics-closes-acquisition-of-stake-in-sod-sciences-and-50-interest-in-pseudohypoxia-test-opening-a-potential-path-to-access-more-than-325-000-new-patients-through-the-aha-channel-1036640947
Vivos Therapeutics Acquires Stake in SOD Sciences and Half Interest in Pseudohypoxia Early-Warning Test
October 19, 2026  |  quiverquant.comQ
Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel
October 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/19/3383925/0/en/vivos-therapeutics-closes-acquisition-of-stake-in-sod-sciences-and-50-interest-in-pseudohypoxia-test-opening-a-potential-path-to-access-more-than-325-000-new-patients-through-the-a.html
Vivos Therapeutics Strikes $12M Stock Deal For SOD Sciences Stake And Test Rights
October 15, 2026  |  rttnews.comhttps://www.rttnews.com/3699485/vivos-therapeutics-strikes-12m-stock-deal-for-sod-sciences-stake-and-test-rights.aspx
Vivos Therapeutics Announces Agreement to Acquire Stake in SOD Sciences and Co-Own Pseudohypoxia Test
October 15, 2026  |  quiverquant.comQ
Vivos Therapeutics targets $3.6 million in annual cost reductions as revenue growth initiatives accelerate
September 29, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/vivos-therapeutics-targets-3-6-million-in-annual-cost-reductions-as-revenue-growth-initiatives-accelerate/ar-AA2dd3WM
Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
September 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3370865/0/en/vivos-therapeutics-reports-progress-in-material-cost-reductions-and-revenue-growth-initiatives.html
Vivos Therapeutics Announces Material Debt Reduction
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357678/0/en/vivos-therapeutics-announces-material-debt-reduction.html
Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference
September 1, 2026  |  newsfilecorp.comN
Vivos Therapeutics Advances South Florida Sleep Center With South Palm Cardiovascular Partnership
August 28, 2026  |  rttnews.comhttps://www.rttnews.com/3686483/vivos-therapeutics-advances-south-florida-sleep-center-with-south-palm-cardiovascular-partnership.aspx

New MarketBeat Followers Over Time

Media Sentiment Over Time

Autonomix Medical stock logo

Autonomix Medical NASDAQ:AMIX

$1.70 +0.18 (+11.84%)
Closing price 04:00 PM Eastern
Extended Trading
$2.13 +0.43 (+25.18%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.

Bone Biologics stock logo

Bone Biologics NASDAQ:BBLG

$0.33 0.00 (-0.63%)
Closing price 03:59 PM Eastern
Extended Trading
$0.35 +0.02 (+5.34%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Venus Concept stock logo

Venus Concept NASDAQ:VERO

$0.31 0.00 (0.00%)
As of 11/6/2026

Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.

Vivos Therapeutics stock logo

Vivos Therapeutics NASDAQ:VVOS

$0.10 +0.00 (+2.24%)
Closing price 04:00 PM Eastern
Extended Trading
$0.10 0.00 (-0.84%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas